Tower Research Capital LLC TRC Raises Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Tower Research Capital LLC TRC lifted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 338.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 19,242 shares of the company's stock after buying an additional 14,852 shares during the period. Tower Research Capital LLC TRC's holdings in IDEAYA Biosciences were worth $495,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Barclays PLC grew its position in IDEAYA Biosciences by 188.8% in the third quarter. Barclays PLC now owns 181,170 shares of the company's stock worth $5,739,000 after acquiring an additional 118,438 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of IDEAYA Biosciences by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 1,988,681 shares of the company's stock valued at $51,121,000 after purchasing an additional 43,226 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of IDEAYA Biosciences by 444.2% in the 4th quarter. SG Americas Securities LLC now owns 18,486 shares of the company's stock valued at $475,000 after purchasing an additional 15,089 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of IDEAYA Biosciences by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 79,780 shares of the company's stock worth $2,527,000 after purchasing an additional 12,029 shares during the period. Finally, WCM Investment Management LLC bought a new position in shares of IDEAYA Biosciences during the 4th quarter valued at approximately $6,030,000. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

IDEAYA Biosciences Price Performance

Shares of IDYA stock traded up $0.46 during mid-day trading on Friday, hitting $20.93. The stock had a trading volume of 1,645,235 shares, compared to its average volume of 970,038. The firm's 50-day moving average is $17.90 and its two-hundred day moving average is $23.05. The firm has a market capitalization of $1.83 billion, a P/E ratio of -6.34 and a beta of 0.26. IDEAYA Biosciences, Inc. has a 12-month low of $13.45 and a 12-month high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported ($1.49) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.82). The business had revenue of $7.00 million for the quarter, compared to analyst estimates of $7.00 million. Analysts expect that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Stephens reaffirmed an "overweight" rating and set a $50.00 price objective on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a report on Monday, January 13th. Finally, Royal Bank of Canada restated an "outperform" rating and set a $61.00 target price on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $53.58.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.